ReviewThe Lancet. Oncology2011
Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
Review in The Lancet. Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 138 citations in OpenAlex.
- Patients with colorectal cancer combined with HIV had a worse overall survival after surgery: a meta-analysis.Frontiers in oncology · 2025Pooled it
- Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.The Lancet. Haematology · 2023Trial
- Southern African HIV Clinicians Society clinical guideline for the management of older people with HIV.Southern African journal of HIV medicine · 2026Article
- Trends in Cancer Diagnoses Among People Living with HIV: A 20-Year Retrospective Study from a Tertiary Center in Thailand.Journal of clinical medicine · 2025Article
- Cancer in children living with HIV: challenges and perspectives in the antiretroviral therapy era.World journal of pediatrics : WJP · 2025Article
- Highly Active Antiretroviral Therapy (HAART) - "Sulfonyl", and anal cancer outcomes from patients living with HIV: a retrospective cohort.Infectious agents and cancer · 2025Article
- Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Navigating the Nexus: HIV and Breast Cancer-A Critical Review.International journal of molecular sciences · 2024Review
- Plasmablastic Lymphoma. A State-of-the-Art Review: Part 2-Focus on Therapy.Mediterranean journal of hematology and infectious diseases · 2024Review
- Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer.AIDS research and therapy · 2022Article
- Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study.The oncologist · 2022Article
- Review
- Hodgkin Lymphoma in People Living with HIV.Cancers · 2021Review
- Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.Pharmacology research & perspectives · 2021Review
- Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice.Cancer management and research · 2021Review
- Hepatitis C Virus Infection and Chemotherapy in Breast Cancer: A Retrospective Chart Analysis.The oncologist · 2020Article
- Haemopoietic cell transplantation in patients living with HIV.The lancet. HIV · 2020Review
- Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments.Critical reviews in oncology/hematology · 2020Review
- Biologic, clinical, and sociodemographic predictors of multi-agent systemic therapy for non-Hodgkin lymphoma in people living with HIV: a population-based investigation in the state of Georgia.Leukemia & lymphoma · 2020Article
- Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-defining cancers and non-AIDS-defining cancers has increased. In this Review we discuss the management of HAART pharmacotherapy in relation to cytotoxic chemotherapy or targeted antineoplastic agents. We will review potential pharmacological interactions between antiretroviral and antineoplastic therapies and consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are receiving HAART therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.